|
|
|
ATOS Description — Atossa Therapeutics Inc
Atossa Therapeutics is a clinical-stage biopharmaceutical company seeking to develop medicines in areas of oncology and infectious diseases, with a focus on breast cancer, other breast conditions and COVID-19. Co.'s drug under development for breast cancer and other breast conditions is Endoxifen which is being developed primarily in two settings: one to reduce tumor cell activity in breast cancer patients in the neoadjuvant setting, meaning prior to surgery; and another to reduce dense breast tissue in women. Co.'s two COVID-19 drugs under development are: AT-H201, an inhalation therapy for COVID-19 patients; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Company Name: |
Atossa Therapeutics Inc |
Website: |
www.atossatherapeutics.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding ATOS: |
2 |
Total Market Value Held by ETFs: |
$8,015,680 |
Total Market Capitalization: |
$212,000,000 |
% of Market Cap. Held by ETFs: |
3.78% |
|
ETF |
ATOS Weight |
ATOS Amount |
VTI |
0.00% |
$5,602,380 |
VXF |
0.00% |
$2,413,300 |
|
|
|
|
Strong Buy (4.00 out of 4)
98th percentile
|
|
|